ライフサイエンスコーパス: cardiac transplant

1 nt patients (-23.9+/-4.9 bpm) (P<.001 versus cardiac transplants).

2 end point of death, HF hospitalization, and cardiac transplant.

3 ilitate opioid withdrawal in children with a cardiac transplant.

4 monitoring for rejection in recipients of a cardiac transplant.

5 ompatibility complex-mismatched vascularized cardiac transplants.

6 tration delays rejection of fully allogeneic cardiac transplants.

7 ally induces donor-specific tolerance to rat cardiac transplants.

8 and maintaining allograft rejection in human cardiac transplants.

9 lograft recipients of islet and vascularized cardiac transplants.

10 cant percentage of sudden cardiac deaths and cardiac transplants.

11 features resemble those observed in rejected cardiac transplants.

12 l disease (GAD) in totally allogeneic murine cardiac transplants.

13 ate coronary artery constriction in men with cardiac transplants.

14 an adjunctive tool in routine monitoring of cardiac transplants.

15 stocompatibility complex class II-mismatched cardiac transplants.

16 in antibody-mediated rejection of renal and cardiac transplants.

17 tumors) into mice with fully MHC mismatched cardiac transplants.

18 to mediate rejection of alphaGal expressing cardiac transplants.

19 ndition, which compromises half of all human cardiac transplants.

20 se or contribute to coronary vasculopathy in cardiac transplants.

21 n liver transplant patients than in renal or cardiac transplants; (2) pravastatin is safe and efficac

22 hickening after balloon injury and in rabbit cardiac transplant allografts.

23 ver the 20-year follow-up (11%), 4 underwent cardiac transplant and 7 died (3 suddenly).

24 de ventricular support to bridge patients to cardiac transplant and may provide an improved quality o

25 tic smooth cell neoplasm occurring following cardiac transplant and the development of two sequential

26 fectious agent to screen for in pig-to-human cardiac transplants and a good model for xenozoonosis.

27 composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-caus

28 PAL FINDINGS: Specimens from 32 autopsies, 8 cardiac transplants, and an excised coronary aneurysm we

29 ischemia is associated with poor survival of cardiac transplants, and ischemic changes in early postt

30 In addition to immediate application in cardiac, transplant, and vascular surgery, the mechanism

31 ring fractional flow reserve (FFR) to assess cardiac transplant arteriopathy has not been evaluated.

32 These data suggest that the human cardiac transplant arteriopathy is associated with reduc

33 Cardiac transplant arteriosclerosis or cardiac allograft

34 total of 380 patients undergoing their first cardiac transplant at 24 centers in the United States, C

35 t PRA screens for 311 patients who underwent cardiac transplant at our institution.

36 A total of 380 patients undergoing de novo cardiac transplants at 24 centers in the United States,

37 group consisted of 68 patients who received cardiac transplants between 1989 and 1996 and who were a

38 udy, we use a novel system of semiallogeneic cardiac transplants between parental donors and F1 hybri

39 in mRNA concentrations were analyzed from 38 cardiac transplant biopsies divided into 3 groups accord

40 long-term survival of vascularized skin and cardiac transplants but not conventional skin grafts.

41 gold standard in rejection surveillance post cardiac transplant, but is invasive, with risk of compli

42 years) with end-stage heart failure who were cardiac transplant candidates eligible for HeartMate imp

43 rounding the use of mechanical assistance in cardiac transplant candidates often leads to multiple bl

44 Selection criteria for cardiac transplant candidates with diabetes mellitus (DM

45 for the retransplant cohort included overall cardiac transplant center volume, the use of a ventricul

46 d retrospectively from a single, high-volume cardiac transplant center.

47 it was limited to select and usually larger cardiac transplant centers and suffered from substantial

48 Questionnaires were sent to 130 cardiac transplant centers in the United States register

49 iac transplant recipients attending the Mayo cardiac transplant clinic in 2000 to 2001, mean of 4.7 y

50 ts in the care of patients who have received cardiac transplants, coronary allograft vasculopathy (CA

51 Competitive template RT-PCR on the cardiac transplants demonstrated similar levels of IL-1-

52 ly consequences of tobacco smoke exposure in cardiac transplant donors and recipients with an emphasi

53 We report on 417 orthotopic cardiac transplants during a 17-year period.

54 Extended criteria cardiac transplant (ECCT) programs expand the transplant

55 the patients who underwent standard criteria cardiac transplant, ECCT patients were older (median, 66

56 was a sample of 82 HF patients referred for cardiac transplant evaluation at an academic medical cen

57 Approximately 50% of cardiac transplants fail in the long term, and currently

58 At a median follow-up of 56 months from cardiac transplant, five of seven patients are alive wit

59 We developed a treatment strategy of cardiac transplant followed by ASCT.

60 lin (ATG) is used as induction therapy after cardiac transplant for enhancing immunosuppression and d

61 rans of CD4(+) T cells in vivo, we performed cardiac transplants from B7-1/B7-2-deficient mice to rec

62 We performed heterotopic MHC class I/II cardiac transplants from BALB/c mice into C57BL/6 mice.

63 systemic inflammation, would correlate with cardiac transplant graft survival.

64 Changes in the RSN rate of both cardiac transplant groups (early, -13.0+/-4.0 bpm; late,

65 baroreflex gains for the DSN and RSN in the cardiac transplant groups were compared with those of th

66 pretransplant sensitization on outcome after cardiac transplant has been controversial.

67 gulated in graft-infiltrating lymphocytes in cardiac-transplanted humans and mice.

68 ay significant roles in the armamentarium of cardiac transplant immunosuppression.

69 tients, partial resection in 21 (23.6%), and cardiac transplant in 4 (4.5%).

70 First, we studied cardiac transplants in fully MHC-mismatched mice that we

71 inhibition induces accommodation of hamster cardiac transplants in nude rats.

72 Long term survival of cardiac transplants in rats treated with the tolerizing

73 erformed vascularized heterotopic allogeneic cardiac transplants in TNF-R1-deficient (TNF-R1(-/-)) an

74 We performed heterotopic murine cardiac transplants in total allogeneic or major histoco

75 data were extended by performing allogeneic cardiac transplants into ICAM or LFA recipients treated

76 In contrast, allogeneic cardiac transplants into IL-6-deficient recipients do no

77 We now recognize that early injury of cardiac transplants involves a newly described form of p

78 Cardiac transplant is hindered by donor shortage and pre

79 megalovirus (CMV) infection in recipients of cardiac transplants is associated with higher rates of m

80 as well as other composite end points (death/cardiac transplant/left ventricular assist device implan

81 experienced the composite end point of death/cardiac transplant/left ventricular assist device implan

82 r and macrovascular disease in patients with cardiac transplants, likely indicating divergent pathoge

83 (STAT)4 and STAT6 as recipients in our mouse cardiac transplant model of chronic rejection.

84 effect of this agent, it was tested in a rat cardiac transplant model of chronic rejection.

85 We used a murine heterotopic cardiac transplant model to identify inflammatory modula

86 The mouse heterotopic cardiac transplant model was employed to evaluate the ef

87 A vascularized murine heterotopic cardiac transplant model was used to test whether periop

88 Using a pig-to-baboon heterotopic cardiac transplant model, we examined the role of antibo

89 +) Treg following CD154 blockade in a murine cardiac transplant model.

90 induce transplantation tolerance in the rat cardiac transplant model.

91 t arteriosclerosis, in the LEW into F344 rat cardiac transplant model.

92 cessory and immune effector cells in a mouse cardiac transplant model.

93 e used NOS2 knockout mice as recipients in a cardiac transplant model.

94 hibited by pravastatin in a well-defined rat cardiac transplant model.

95 lerance in the nonfunctional rat heterotopic cardiac transplant model.

96 xpression, and iNOS enzyme activity in a rat cardiac transplant model.

97 and 14-day course of CsA in the ACl-to-Lewis cardiac transplant model.

98 splantation in a BALB/c into B6 vascularized cardiac transplant model.

99 ponse in the setting of cold I/R in a murine cardiac transplant model.

100 Two murine cardiac transplant models were used, B10.D2 (minor misma

101 Using murine skin and cardiac transplant models, the authors demonstrate that

102 acute and chronic rejection in experimental cardiac transplant models.

103 nct temporal and spatial patterns in two rat cardiac transplant models: either with antigenic challen

104 Among selected patients who had received a cardiac transplant more than 6 months previously and who

105 bubbles to rejecting versus nonrejecting rat cardiac transplant myocardium can be detected ultrasonic

106 sudden death, n=71; and noncardiac, n=22) or cardiac transplant (n=36).

107 psies (n=3), endomyocardial biopsy (n=1), or cardiac transplants (n=2) showed marked myocyte hypertro

108 , 15 eligible RCTs involving 643 patients (9 cardiac transplants [n=250 patients], 2 kidney transplan

109 ubject to tissue-specific autoimmunity) with cardiac transplants (not subject to tissue-specific auto

110 ican Americans, with an adjusted RR of death/cardiac transplant of 1.95 (95% CI = 1.21-3.13) for hete

111 in survival with a relative risk of death or cardiac transplant of 4.81 (P < 0.001) compared with tho

112 based protocol and inspection at the time of cardiac transplant or corrective surgery.

113 ompatibility complex-mismatched vascularized cardiac transplants or skin transplants were performed u

114 of Science databases using the search terms "cardiac transplant" or "heart transplant," and "statin"

115 ionship between increasing center volume and cardiac transplant outcomes.

116 in Neoral-treated de novo renal, liver, and cardiac transplants (P<0.05).

117 ulmonary and cerebral phaeohyphomycosis in a cardiac transplant patient due to a newly identified spe

118 The risk of opportunistic infection in the cardiac transplant patient is determined by the interact

119 are an indication for cholecystectomy in the cardiac transplant patient.

120 culating endothelin-1 and acute rejection in cardiac transplant patients (sensitivity of 100% and spe

121 of cyclosporine has improved the survival of cardiac transplant patients as a result of reduced morbi

122 More than 20% of cardiac transplant patients go on to require permanent p

123 Cardiac transplant patients had significantly lower BMD

124 to combination immunosuppressive regimens in cardiac transplant patients has resulted in significant

125 Approximately one fourth of cardiac transplant patients require permanent pacing.

126 tigated endomyocardial biopsy specimens from cardiac transplant patients to determine whether apoptos

127 N) in the innervated remnant right atrium in cardiac transplant patients were compared with heart rat

128 Sixty-eight cardiac transplant patients were randomized to receive e

129 en June 1999 and November 2004, 94 pediatric cardiac transplant patients were screened for the presen

130 In a sequential study, 240 cardiac transplant patients were treated with either MMF

131 lticenter, randomized, double-blind study in cardiac transplant patients were: to compare the efficac

132 -control study nested within a cohort of 189 cardiac transplant patients who had blood samples obtain

133 ponin-T concentrations were obtained from 68 cardiac transplant patients who were followed for 68.8+/

134 in a significant proportion of asymptomatic cardiac transplant patients with normal angiograms.

135 Cardiac transplant patients with pretransplant T- and/or

136 ease, a major cause of late graft failure in cardiac transplant patients, is associated with the pres

137 mortality from gallstone disease is high in cardiac transplant patients, particularly immediately po

138 dies to evaluate the role of statins in post-cardiac transplant patients, specifically examining the

139 ed the beneficial effects of statins in post-cardiac transplant patients, these were relatively small

140 Its role in cardiac transplant patients-including its incidence, mec

141 uman endomyocardial biopsies (n=101) from 10 cardiac transplant patients.

142 tase inhibitors for the prevention of GVD in cardiac transplant patients.

143 uble-blind study to confirm these results in cardiac-transplant patients.

144 ncluding cardiac recovery, time to recovery, cardiac transplant, persistent dysfunction, and death, w

145 rmine the incidence of cardiac pacing in our cardiac transplant population and identify characteristi

146 The current cardiac transplant population differs from earlier perio

147 SCD occurs relatively frequently in the cardiac transplant population, and CAD is present in mos

148 current data on time-dependent changes in US cardiac transplant practice and survival.

149 From 1990 to 1995, 70 consecutive adult cardiac transplant procedures were performed without an

150 c distinction between these 2 different post-cardiac transplant processes should prove useful to card

151 Rats undergoing cardiac transplants received NOX-100, a water-soluble ni

152 t a case of fatal infection in a 78-year-old cardiac transplant recipient and discuss pitfalls in the

153 Twenty cardiac transplant recipient rabbits were treated with e

154 Our first case involved a 40-year-old male cardiac transplant recipient with multiple localized ski

155 pseudolymphomatous pericardial effusion in a cardiac transplant recipient.

156 rvival and quality of life for the pediatric cardiac transplant recipient.

157 has been reported only once previously in a cardiac transplant recipient.

158 Five hundred thirty-one cardiac transplant recipients (age >/=18 years) were eva

159 cise tests performed in 57 clinically stable cardiac transplant recipients (mean age, 45 +/- 2 years)

160 CNI was substituted with SRL in 78 cardiac transplant recipients (SRL group) of whom 58 (gr

161 We recruited 90 renal and cardiac transplant recipients and 72 age-matched control

162 We reviewed medical records of cardiac transplant recipients and compared baseline char

163 ting plasma homocysteine was measured in 189 cardiac transplant recipients and in healthy controls, a

164 e reversibility of pulmonary hypertension in cardiac transplant recipients and to identify clinical r

165 We conclude that cardiac transplant recipients are at increased risk for

166 Published experiences with PTLD in cardiac transplant recipients are limited to relatively

167 blood T lymphocytes obtained from pediatric cardiac transplant recipients at the time of biopsy and

168 e blood samples were obtained from pediatric cardiac transplant recipients at the time of cardiac bio

169 easurements via a conductance catheter in 20 cardiac transplant recipients at the time of clinically-

170 scending coronary artery was performed in 30 cardiac transplant recipients at year 1 and 2 after tran

171 ained and stored from a cross-section of 112 cardiac transplant recipients attending the Mayo cardiac

172 This multicenter, randomized study of cardiac transplant recipients documented less severe rej

173 levels may play a role in the management of cardiac transplant recipients during the first year post

174 coronary endothelial dysfunction observed in cardiac transplant recipients during treatment with simv

175 report here the first use of bortezomib for cardiac transplant recipients in four pediatric heart re

176 biopsy enables prospective stratification of cardiac transplant recipients into risk categories for p

177 antibodies (DSA) and positive crossmatch in cardiac transplant recipients is associated with increas

178 PTLD in cardiac transplant recipients is associated with low lon

179 Humoral or antibody-mediated rejection in cardiac transplant recipients is mediated by donor-speci

180 Graduated substitution of CNI with SRL in cardiac transplant recipients is safe and improves renal

181 he efficacy and tolerability of ezetimibe in cardiac transplant recipients receiving cyclosporin.

182 resents experience with 274 cases of PTLD in cardiac transplant recipients reported to the Israel Pen

183 ithdrawal of CNI and replacement with SRL in cardiac transplant recipients results in a decrease in L

184 etection and treatment of acute rejection in cardiac transplant recipients significantly improves lon

185 etimibe is both efficacious and tolerable in cardiac transplant recipients taking cyclosporin.

186 Posttransplantation nephrotoxicity in cardiac transplant recipients treated with CsA for a lon

187 Thirty-eight adult cardiac transplant recipients underwent coronary angiogr

188 Forty-five cardiac transplant recipients were converted to sirolimu

189 Twenty-nine cardiac transplant recipients were converted to SRL 3.8+

190 Seventy cardiac transplant recipients were converted to SRL, 5.7

191 Yet cardiac transplant recipients were generally free of opp

192 performed at LDS and University Hospitals in cardiac transplant recipients were reviewed and compared

193 Forty-six consecutive cardiac transplant recipients were sampled at 1, 3, 6, a

194 Cardiac transplant recipients who engaged in an exercise

195 fects of nitric oxide on heart rate in human cardiac transplant recipients who possess a denervated d

196 Seventy-three consecutive cardiac transplant recipients who received an OKT3-based

197 We studied 99 consecutive cardiac transplant recipients who were referred for rout

198 e role of MMF therapeutic drug monitoring in cardiac transplant recipients will be discussed.

199 Thirty-four cardiac transplant recipients with a previous history of

200 l vascular endothelial function is normal in cardiac transplant recipients with antecedent nonischemi

201 Long-term treatment of cardiac transplant recipients with cyclosporine results

202 The proportion of cardiac transplant recipients with preexisting sensitiza

203 hat there is an increased mortality risk for cardiac transplant recipients with prior HD who have und

204 (n = 10) or ischemic cardiomyopathy (n = 7), cardiac transplant recipients with prior nonischemic car

205 the positive and negative effects of ISM in cardiac transplant recipients with PTLD.

206 In 53 cases of asymptomatic cardiac transplant recipients without angiographically s

207 end of the first posttransplantation year in cardiac transplant recipients without resumption of rapi

208 Among the group of 195 cardiac transplant recipients, actuarial survival was 72

209 Tobacco exposure in cardiac transplant recipients, before and after transpla

210 iae DNA is detectable by PCR in up to 30% of cardiac transplant recipients, but this does not correla

211 termine short-term and long-term outcomes of cardiac transplant recipients, including an increased in

212 ely matched to endomyocardial biopsies in 98 cardiac transplant recipients, who survived >/=3 months

213 on-related coronary artery disease (TCAD) in cardiac transplant recipients.

214 F in renal-sparing regimens and in pediatric cardiac transplant recipients.

215 tant implications for ISM in PTLD therapy in cardiac transplant recipients.

216 te cyclosporine-associated nephrotoxicity in cardiac transplant recipients.

217 ly to prevent allograft rejection, mostly in cardiac transplant recipients.

218 ameliorate CsA-associated nephrotoxicity in cardiac transplant recipients.

219 n is safe and highly effective in sensitized cardiac transplant recipients.

220 ty cTnI assay seems useful to rule out AR in cardiac transplant recipients.

221 exes of diastolic performance in a cohort of cardiac transplant recipients.

222 peripheral vascular endothelial function in cardiac transplant recipients.

223 ociated with subsequent allograft failure in cardiac transplant recipients.

224 and donor cause of death on survival in 500 cardiac transplant recipients.

225 ar rejection in endomyocardial biopsies from cardiac transplant recipients.

226 mens are still inadequate in the majority of cardiac transplant recipients.

227 immune activation and possible rejection in cardiac transplant recipients.

228 rs, and clinical outcome was evaluated among cardiac transplant recipients.

229 with invasively-demonstrated LV stiffness in cardiac transplant recipients.

230 ic AR and lower 2 year allograft survival in cardiac transplant recipients.

231 o be an important immunosuppressive agent in cardiac transplant recipients.

232 l failure, requiring hemodialysis in 6.5% of cardiac transplant recipients.

233 nt recipients prompted a randomized trial in cardiac transplant recipients.

234 d during the 14-day OKT3 induction course in cardiac transplant recipients.

235 tudy used the explanted hearts of five human cardiac transplant recipients.

236 ant risk factor for coronary vasculopathy in cardiac transplant recipients.

237 neated in the left ventricles (LVs) of human cardiac transplant recipients.

238 ial survival rate at 5 years was 80% for the cardiac transplant recipients.

239 s a routine test for predicting prognosis in cardiac transplant recipients.

240 compared between ECCT and standard criteria cardiac transplant recipients.

241 an important adjunct to treatment of AMR in cardiac transplant recipients.

242 pendent predictor of graft loss in pediatric cardiac transplant recipients.

243 d replacement with sirolimus (SRL) in stable cardiac transplant recipients.

244 onal advantage from the use of everolimus in cardiac transplant recipients.

245 , and IgA concentrations were measured in 33 cardiac-transplant recipients transplanted before the ag

246 We studied 14 cardiac-transplant recipients who had normal coronary ar

247 ipients and, in a single-center trial, among cardiac-transplant recipients.

248 ptor (daclizumab) was performed in 70 adult, cardiac-transplant recipients.

249 splant Study (1993 to 2002, n = 367) and the Cardiac Transplant Registry Database (1990 to 2002, n =

250 imaging technique for the detection of acute cardiac transplant rejection and other processes charact

251 Noninvasive techniques for detecting acute cardiac transplant rejection are limited.

252 uced immune-mediated tissue injury following cardiac transplant rejection, an in vivo model of intens

253 ases of the heart, including myocarditis and cardiac transplant rejection, are important causes of mo

254 cells into the heart during inflammation and cardiac transplant rejection.

255 echanism that may play a significant role in cardiac transplant rejection.

256 ildren and may be a potential contributor to cardiac transplant rejection.

257 mote cardiovascular diseases including acute cardiac transplant rejection; however, the contribution

258 ial biopsy is the major method for detecting cardiac transplant rejection; however, this approach is

259 Members of the Cardiac Transplant Research Database Group developed and

260 of these and other events is the goal of the Cardiac Transplant Research Database group.

261 At the time of this analysis, the Cardiac Transplant Research Database included all 2749 p

262 We measured these secular trends in the Cardiac Transplant Research Database to provide current

263 Utilizing the data from the Cardiac Transplant Research Database, the clinician may

264 , and results of the published data from the Cardiac Transplant Research Database.

265 Current practice in the monitoring of cardiac transplants revolves around the use of the endom

266 dial effusion is frequently seen in the post-cardiac transplant setting, EBV-related PTLD may also pr

267 fter coronary artery bypass graft surgery or cardiac transplant surgery and during or after angioplas

268 th periodate-oxidized ATP promotes long-term cardiac transplant survival in 80% of murine recipients

269 y investigates the role of these pathways in cardiac transplant survival in recipients treated with a

270 baseline characteristics, standard criteria cardiac transplant survival was higher than ECCT at 1 (8

271 ovel clinically relevant strategy to prolong cardiac transplant survival.

272 Mouse-to-rat cardiac transplants survive long term after transient co

273 transplant processes should prove useful to cardiac transplant teams.

274 In patients who have received a cardiac transplant, the denervated donor heart responds

275 O-1 suppresses the rejection of mouse-to-rat cardiac transplants through a mechanism that involves th

276 suppressive regimen that allows mouse-to-rat cardiac transplants to survive long term (i.e., cobra ve

277 ovel mechanism of donor ECDI-SPs in inducing cardiac transplant tolerance and provide several targets

278 ospot, signaling studies, and a rat model of cardiac transplant tolerance induced by administration o

279 randomly assigned 434 recipients of a first cardiac transplant treated with standard immunosuppressi

280 Initial human cardiac transplant trials suggest that OKT4A does not ca

281 The growth of the US cardiac transplant waiting list has outpaced the increas

282 Cardiac transplant was associated significantly with hig

283 Long-term survival of cardiac transplants was associated with reduced T-cell a

284 Both DST and the cardiac transplant were necessary to generate the regula

285 In contrast, cardiac transplants were not rejected by aly/aly-spl(-)

286 iac allografts in large animals, heterotopic cardiac transplants were performed across a class I MHC

287 Between April 1985 and October 2000, 518 cardiac transplants were performed at Ochsner Foundation

288 The cardiac transplants were performed first.

289 Rat heterotopic abdominal cardiac transplants were performed using a Lewis to Fisc

290 expression on the donor vasculature, murine cardiac transplants were performed using homozygous P-se

291 (BALB/c into C57/B16) heterotopic abdominal cardiac transplants were performed.

292 0 consecutive eligible recipients of primary cardiac transplants were randomly assigned to standard t

293 us transgenic CD46 pig-to-baboon heterotopic cardiac transplants were reanalyzed for baseline immunos

294 CBA/CaJ to C57BL/6J vascularized cardiac transplants were treated with murine CTLA4Ig del

295 We treated mice with HLA-mismatched mouse cardiac transplant with atorvastatin and dasatinib and s

296 stribution of B cells and plasma cells in 16 cardiac transplants with advanced chronic rejection that

297 ncreased in coronary arteries dissected from cardiac transplants with arteriopathy, but the prevelanc

298 cted class II disparate and fully allogeneic cardiac transplants with similar kinetics.

299 rospectively recruited patients who received cardiac transplants within the same period as the interv

300 ement for left ventricular assist device, or cardiac transplant] within the first 2 years of presenta